Sygnature Discovery helps biotech and pharmaceutical companies increase efficiency

Follow the link to see Sygnature Discovery’s Case Study in the latest Creative Quarter publication: Read more…

Sygnature Discovery is pleased to be sponsoring Oxford Biotech’s The Future of Drug Discovery: Open Innovation on December 4th 2014 at the University of Oxford

The evening features talks from a range of high profile experts from industry and academia on the future of drug discovery research and is followed by panel discussions and questions from the audience. If you are interested in attending this free event please click on the link below:   The Future of Drug Discovery: Open […]

‘Aspects of Modern Drug Discovery’ – Speaker Summaries

The first guest speaker to take to the podium at Sygnature’s symposium on October 7th 2014, was Dr Jonathan Rachman from MapMy Health. In the early 1990s, a small group of academic units around the world was taking an interest in the physiological effects of the gut hormone glucagon-like peptide-1 (GLP-1), with a view to […]

Sygnature Celebrates 10 Years of Drug Discovery

On Tuesday 7th October 2014 Sygnature Discovery celebrated its 10th anniversary by hosting a symposium on ‘Aspects of Modern Drug Discovery’. Held at Nottingham’s East Midlands Conference Centre, seven distinguished scientific speakers were invited to talk to a packed audience of two hundred guests. The event came to a close with a drinks reception to […]

BerGenBio granted a prestigious Wellcome Trust Seeding Drug Discovery Award

NOK 16 million awarded to develop novel cancer Bergen, Norway, September 23, 2014 – BerGenBio AS (“BerGenBio” or the “Company”), an oncology biopharmaceutical company, today announces it has been granted a £1.6 million (NOK 16 million) Seeding Drug Discovery Award from the UK’s Wellcome Trust to develop novel small molecule inhibitors against BGB002, its proprietary, […]

Page 14 of 15« First...1112131415
Copyright © 2018 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.